This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. ICD-10 code | E83.3 | Special Copayment Reduction: V189 |
| B. Synonyms | Acid phosphatase deficiency, lysosomal acid phosphatase deficiency, Lysosomal acid phosphatase deficiency, ACP2 deficiency, lysosomal storage disorder (lysosomal acid phosphatase deficiency) |
| C. Adult onset | Likelihood of first presentation in adulthood: low — an ultra-rare disease that mostly presents in the neonatal period or infancy with severe neurological and multisystem abnormalities, with survival to adulthood extremely rare |
| 1. History | History of very few case reports; discovery of the ACP2 gene and animal model studies |
| 2. Causes | ACP2 gene mutation → deficient lysosomal acid phosphatase activity |
| 3. Genetics | Autosomal recessive; ACP2 gene (11p11.2) |
| 4. General epidemiology | Fewer than several dozen cases worldwide; exact prevalence unknown |
| 5. Pathophysiology | Impaired hydrolysis of phosphate esters within lysosomes → intracellular substrate accumulation → multisystem dysfunction |
| 6. Symptoms | Severe neurological abnormalities in the neonatal period, seizures, growth delay, skeletal abnormalities, skin and hair abnormalities |
| 7. Signs | Neurological regression, cerebellar dysfunction (ataxia), bone structural abnormalities, intracellular storage abnormalities |
| 8. Screening | Lysosomal enzyme panel testing; newborn metabolic screening; molecular genetic testing |
| 9. Diagnosis | Measurement of ACP2 enzyme activity in leukocytes and fibroblasts; identification of ACP2 gene variants |
| 10. Treatment | Mainly supportive care; seizure control, nutritional support; no established definitive treatment |
| 11. Prognosis | Early death in severe forms; long-term prognosis data extremely limited |
| 12. Prevention | Genetic counseling; prenatal diagnosis; family screening |
| 13. References | 10 key references |
Lysosomal Acid Phosphatase (LAP) deficiency is an ultra-rare lysosomal storage disease for which only a very small number of cases have been reported worldwide. Storage diseases due to lysosomal enzyme deficiencies began to be studied in earnest after Christian de Duve discovered the lysosome in 1965 and the link between lysosomal enzyme deficiencies and metabolic diseases was subsequently established. Unlike the dozens of lysosomal storage diseases that have been described, such as Gaucher disease and Fabry disease, the human clinical phenotype of LAP deficiency remained unclear for a long time.
In 1968, Nadler and Egan reported markedly reduced acid phosphatase activity in red blood cells and tissues of an infant who showed severe neonatal seizures, neurological regression, and hepatosplenomegaly. This case is regarded as an early human report of LAP deficiency. However, additional case reports were very rare over the following decades, making it difficult to grasp the full spectrum of the disease.
Understanding at the gene level advanced greatly through animal model studies. In knockout mouse studies targeting the Acp2 gene (in mice), Harthun et al. reported in 2004 that Acp2-deficient mice show severe growth delay, structural abnormalities of the cerebellar cortex, an ataxia-like phenotype, spinal kyphoscoliosis, hair abnormalities, and a tendency to seizures. This model has made a key contribution to research on the pathophysiology of human ACP2 deficiency.
Since the 2010s, with advances in next-generation sequencing (NGS) technology, pathogenic variants in the ACP2 gene have begun to be identified, rarely, in patients with lysosomal storage diseases of unknown cause. To date, only a few human cases have been reported in the literature, and systematic knowledge of the clinical spectrum, natural history, and treatment response is still lacking. This disease is listed in OMIM under number 200950 (ACP2 deficiency), and it is so rare that GeneReviews has no separate entry for it.
The cause of lysosomal acid phosphatase deficiency is the presence of pathogenic variants on both alleles of the ACP2 (acid phosphatase 2, lysosomal) gene. ACP2 is an acid phosphatase located in the lysosome, belonging to the histidine acid phosphatase family, and hydrolyzes a wide range of phosphate ester substrates in an acidic environment of pH 4~6.
The ACP2 protein functions as a heterodimer composed of two subunits (α: ACP3 gene product, β: ACP2 gene product). Therefore, variants in the ACP3 gene may also cause enzyme deficiency, but human reports have focused mainly on ACP2 variants. Within the lysosome, ACP2 is involved in the hydrolysis steps of glycolipids, glycoproteins, nucleotides, and phosphorylated proteins, contributing to lysosomal substrate processing and intracellular phosphate recycling.
When ACP2 function is deficient, phosphate ester hydrolysis does not occur within the lysosome, and various substrates accumulate in the cell. Exactly which substrate is toxic has not yet been fully elucidated, but lysosomal dysfunction in neurons is presumed to cause neurodegeneration and seizures, and dysfunction of osteoblasts and osteoclasts to cause bone structural abnormalities. Lysosomal dysfunction in skin and hair cells has also been proposed as the mechanism explaining the related phenotypes.
There is a hypothesis that the lysosome-autophagy pathway may be secondarily affected and may also be linked to mitochondrial function. However, because this is based on a small number of cases and animal model studies, further research is needed.
Lysosomal acid phosphatase deficiency follows an autosomal recessive (AR) mode of inheritance. The causative gene ACP2 is located on the short arm of chromosome 11 (11p11.2) and consists of 11 exons. The protein consists of 423 amino acids and is transported to the lysosome via an N-terminal signal sequence.
The number of ACP2 pathogenic variants reported in human patients to date is very small. Reported variants include missense, nonsense, and splicing variants. In animal models (mice), loss of Acp2 function, whether naturally occurring or due to genetic engineering, reproduces various phenotypes and is used in research. Because inheritance is AR, when both parents are carriers, 25% of their children are affected. Carriers have enzyme activity of about 50% of normal but no clinical symptoms.
Genotype-phenotype correlations have not been established because of the extremely limited clinical data. Because ACP3 (distinct from prostatic acid phosphatase), as an isoform of ACP2, functions as the α subunit of the complex, ACP3 variants may also cause a similar phenotype. In suspected patients, differentiation from variants in other lysosomal enzyme genes through a full lysosomal enzyme panel and exome/genome sequencing is necessary.
Lysosomal acid phosphatase deficiency is one of the rarest lysosomal storage diseases in the world. As of 2024, confirmed or strongly suspected human cases reported in the world literature number only from a few to a few dozen, and the exact prevalence is not known. The combined prevalence of all lysosomal storage diseases is about 1/5,000~1/7,000, but the proportion accounted for by ACP2 deficiency is extremely small.
No domestic cases have been identified in the official literature, and the number of patients registered for Special Copayment Reduction is also expected to be very small. Because of its extreme rarity, almost no specialists have experience diagnosing it, and it is highly likely to be misdiagnosed as another lysosomal storage disease or a neurodegenerative disease of unknown cause. As next-generation sequencing (NGS) and whole exome/genome sequencing become routine, previously undiagnosed patients are beginning to be identified, so the actual prevalence may be higher than previous estimates.
Differences in incidence by sex, ethnicity, or region are unknown because of insufficient reported data. Because it is an autosomal recessive disease, there is theoretically no sex bias.
The core pathophysiology of ACP2 deficiency is a variety of cellular dysfunctions due to impaired processing of phosphate ester substrates within the lysosome. The lysosome is the digestive organelle of the cell, breaking down macromolecules from inside and outside the cell through autophagy, endocytosis, and phagocytosis. ACP2 is responsible for hydrolyzing phosphate ester bonds in this process.
When ACP2 function is lost, substrates accumulate within the lysosome, causing lysosomal swelling and cellular dysfunction. In the nervous system, lysosomal dysfunction leads to neuronal death, glial cell reactions, and synaptic dysfunction. In animal models, structural abnormalities of the granule cell layer and Purkinje cells of the cerebellar cortex are prominent, which form the basis of the clinical ataxia phenotype. Lysosomal storage abnormalities are also observed in the cerebral cortex, leading to seizures and cognitive decline.
In the skeletal system, osteoclasts use lysosomal enzymes to break down bone matrix. In ACP2 deficiency, the bone resorption function of osteoclasts becomes abnormal and the osteoblast-osteoclast balance is disrupted, causing bone structural abnormalities. In animal models, thoracolumbar kyphoscoliosis and spinal deformity appeared progressively after 6 months of age.
In skin and hair, lysosomal dysfunction of keratinocytes within hair follicles causes abnormal keratinization and hair structural abnormalities. These multisystem phenotypes reflect that ACP2 is an essential component of lysosomal function in many tissues.
Reported human cases of ACP2 deficiency are extremely rare, making it difficult to describe the clinical spectrum fully. The clinical features, synthesizing animal model studies and sporadic case reports, are as follows.
Neurological symptoms: Early seizures in the neonatal period or infancy are characteristically reported. Seizures are often difficult to control, and various seizure types (clonic, tonic, tonic-clonic, etc.) may occur. Progressive neurological regression develops, with delayed motor development, abnormal muscle tone (hypotonia or hypertonia), and impaired motor coordination (ataxia). Cognitive development may also be impaired.
Skeletal symptoms: Spinal kyphoscoliosis and long bone abnormalities, which are prominent in animal models, may occur similarly in human patients. Growth delay and short stature also accompany.
Skin and hair symptoms: Abnormal hair morphology, sparse hair, and hair structural abnormalities may accompany. Abnormal skin keratinization has also been reported in some patients.
Other symptoms: Multisystem symptoms such as hepatosplenomegaly, feeding difficulties, and recurrent infections may accompany. The early case report (Nadler and Egan, 1968) described neonatal seizures, hypotonia, hepatosplenomegaly, and death. In surviving patients, severe intellectual disability, absent language development, and persistent seizures have been reported.
Neurological signs: On physical examination, increased or absent deep tendon reflexes, signs of cerebellar ataxia (inability to tandem walk, impaired limb coordination, nystagmus), and abnormal muscle tone are observed. In infants, a bulging anterior fontanelle (with raised intracranial pressure) may appear.
Brain imaging signs: Brain MRI may show cerebellar atrophy, cerebral cortical atrophy, and abnormal white matter signal. Accumulation of lysosomal storage material within neurons may cause abnormal brain MRI signals. Epileptiform discharges (EEG abnormalities) are confirmed on electroencephalography.
Laboratory signs: A marked reduction of ACP2 enzyme activity in leukocytes or fibroblasts is the diagnostic finding. Total serum acid phosphatase activity may also be reduced, but this may be partially compensated by ACP3 (other isoenzymes such as prostatic acid phosphatase) activity. Measurement of urinary oligosaccharides or glycolipids reflecting lysosomal storage abnormalities may be positive in some cases.
Pathologic findings: Electron microscopy (EM) shows swollen lysosomes and abnormal storage material in various cells. Brain biopsy may show storage vacuoles within neurons and loss of the cerebellar granule cell layer.
Imaging findings: X-rays may show spinal kyphoscoliosis and long bone abnormalities. Abdominal ultrasound may confirm hepatosplenomegaly.
Currently, no country performs official newborn screening for lysosomal acid phosphatase deficiency. It may possibly be included in general lysosomal storage disease screening, but this has not been standardized.
Screening at the stage of clinical suspicion: In patients presenting simultaneously with unexplained neonatal/infantile seizures, hypotonia, neurological regression, and hepatosplenomegaly, a panel test is performed to exclude all lysosomal storage diseases. This panel includes Gaucher, Niemann-Pick, GM1/GM2 gangliosidosis, multiple sulfatase deficiency, and others.
Lysosomal enzyme panel: Screening is possible when a panel test that simultaneously measures multiple lysosomal enzyme activities in serum or leukocytes includes acid phosphatase activity. However, many institutions do not include ACP2-specific measurement in their standard lysosomal panel.
Molecular genetic screening: In patients with neurodegeneration of unknown cause, discovery of ACP2 gene variants through whole exome sequencing (WES) or whole genome sequencing (WGS) is the realistic diagnostic pathway. Investigation of family history and checking for consanguineous marriage help in suspecting an AR disease.
Enzyme activity measurement: The key to diagnosis is confirmation of ACP2 enzyme activity. Total acid phosphatase activity and, if possible, ACP2-specific activity are measured in leukocytes, skin fibroblasts, or dried blood spots (DBS). Confirmation requires an enzyme assay using an ACP2-specific substrate, which is available only at specialized research institutions. Reduced enzyme activity (less than 10% of normal) is the confirmation criterion.
Molecular genetic diagnosis: Pathogenic variants on both alleles are confirmed by direct sequencing of the ACP2 gene (Sanger sequencing or NGS-based panel/WES/WGS). When a variant is found on only one allele, analysis for large deletions/duplications (MLPA, array CGH) may be needed.
Supplementary diagnosis: Brain MRI (to identify cerebellar/cerebral abnormalities), EEG (to determine seizure type), abdominal ultrasound (hepatosplenomegaly), skeletal X-rays (spinal and long bone abnormalities), and skin or brain biopsy with electron microscopy (lysosomal storage abnormalities) are used to support diagnosis.
Differential diagnosis: Differentiation is needed from other lysosomal storage diseases such as GM1 gangliosidosis, GM2 gangliosidosis (Tay-Sachs, Sandhoff), Niemann-Pick disease type A, Wolman disease (acid lipase deficiency), multiple sulfatase deficiency, and neuronal ceroid lipofuscinosis (NCL), as well as mitochondrial encephalopathy and neonatal seizures of unknown cause.
To date, there is no approved specific treatment (enzyme replacement therapy, substrate reduction therapy, gene therapy, etc.) for lysosomal acid phosphatase deficiency. Treatment centers on symptom control and supportive care.
Seizure treatment: Seizure control with antiepileptic drugs (AED) is the most important treatment. Because multidrug-resistant seizures are common, several agents such as levetiracetam, valproic acid, and clonazepam are used in combination. A ketogenic diet is sometimes partially effective for refractory seizures.
Nutritional and growth support: When there are feeding difficulties, feeding via a nasogastric tube or percutaneous gastrostomy tube (PEG) is considered. When growth hormone deficiency is present, supplementation can be discussed, but evidence is lacking.
Rehabilitation: Motor function and activities of daily living are maintained as much as possible through physical therapy and occupational therapy.
Investigational treatments: Research on enzyme replacement therapy, hematopoietic stem cell transplantation, and gene therapy for lysosomal storage diseases in general is in progress, and specific research on ACP2 deficiency is being attempted in animal models. Hematopoietic stem cell transplantation is effective in preserving neurological function in some lysosomal storage diseases, but there is no clinical experience with it in ACP2 deficiency.
Multidisciplinary approach: Management is by a multidisciplinary team consisting of pediatric neurology, a metabolic specialist, a genetic counselor, orthopedics, a dietitian, a physical therapist, and an occupational therapist.
Systematic data on the prognosis of lysosomal acid phosphatase deficiency are very limited. Taking the reported cases together, severe forms often result in early death in the neonatal period or infancy. In the first reported case (1968), the infant also died within a few weeks. Even in surviving cases, severe neurological sequelae (severe intellectual disability, seizures, loss of motor function) are reported to remain.
In animal models, Acp2-deficient mice survive to adulthood, but growth delay, cerebellar ataxia-like behavior, and spinal deformity progressively worsen. Whether this applies equally to humans is uncertain. The possibility of long-term survivors with a mild phenotype in humans cannot be excluded, but none have been reported.
Because there is currently no specific treatment, ways to change the natural history are limited. For symptom control, a palliative approach focused on maintaining quality of life and minimizing complications is realistic. If gene therapy or enzyme replacement therapy is developed, prognosis could improve, but these are not at the clinical stage.
Lysosomal acid phosphatase deficiency is an autosomal recessive genetic disease, and there is no direct way to prevent its onset itself. However, recurrence within the family can be prevented through genetic counseling and prenatal diagnosis.
Genetic counseling: Parents of a confirmed patient should have their carrier status confirmed and receive counseling on the risk of occurrence in subsequent pregnancies (25%). Because consanguineous marriage raises carrier frequency and increases the risk of AR diseases, prenatal screening is especially important in consanguineous families.
Prenatal diagnosis: When an ACP2 pathogenic variant has been identified in the family, fetal DNA can be obtained by chorionic villus sampling (11~14 weeks of gestation) or amniocentesis (16~20 weeks of gestation) for molecular genetic testing. Prenatal diagnosis through enzyme activity measurement is also theoretically possible but available only at specialized institutions.
Preimplantation genetic diagnosis (PGD): A method can be used in which, together with in vitro fertilization (IVF), embryos are tested for ACP2 variants and unaffected embryos are selected for transfer.
Family screening: In siblings of a confirmed patient, confirmation of carrier status and presymptomatic diagnosis through enzyme activity measurement or genetic testing are important. When early diagnosis is made, early intervention with supportive care is possible.